Loading
Ondansetron (Zofran) was the drug that made cisplatin-type chemotherapy bearable. It blocks the serotonin signal that triggers vomiting and is now a cheap generic tablet, dissolving wafer or injection used across cancer care.
Ondansetron was approved in January 1991 for prevention of nausea and vomiting from highly emetogenic chemotherapy including cisplatin, with moderately emetogenic chemotherapy, radiotherapy (total body irradiation and abdominal fields) and post-operative nausea added later, and oral, orally disintegrating, film and injectable forms available. Its introduction, the first selective 5-HT3 antagonist, transformed supportive care and it remains the backbone of antiemetic prophylaxis worldwide and on the WHO essential medicines list. QT prolongation led the FDA to withdraw the 32 mg single intravenous dose in 2012; headache and constipation are common and serotonin syndrome is a rare interaction. Palonosetron and granisetron are the longer-acting alternatives.
Selective antagonist of serotonin 5-HT3 receptors on vagal afferent nerves and in the chemoreceptor trigger zone; blocks the serotonin surge released from enterochromaffin cells by chemotherapy and radiation.
1.Ondansetron slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1991 | Prevention of nausea and vomiting from highly emetogenic chemotherapy; later moderately emetogenic chemotherapy, radiotherapy and post-operative nausea |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ondansetron" OR ABSTRACT:"Ondansetron" OR TITLE:"Zofran" OR ABSTRACT:"Zofran" OR TITLE:"Zuplenz oral film" OR ABSTRACT:"Zuplenz oral film") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ondansetron, not a curated reading list.
Shares Hikma Pharmaceuticals, Aprepitant (and fosaprepitant), Oral solid dose manufacturing (tablets and capsules), Antiemetics for chemotherapy-induced nausea and vomiting and the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares Aprepitant (and fosaprepitant), Palonosetron, Antiemetics for chemotherapy-induced nausea and vomiting and the tag supportive.
Shares Aprepitant (and fosaprepitant), Antiemetics for chemotherapy-induced nausea and vomiting and the tag supportive.